- $84.29m
- $49.73m
- $10.66m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.91 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -62.06% | ||
| Return on Equity | -767.91% | ||
| Operating Margin | -239.69% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | 12.5 | n/a | 10.65 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Surrozen, Inc. is a biotechnology company discovering and developing drug candidates to selectively modulate the Wnt pathway. The Company is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a focus in ophthalmology. Its product candidates include SZN-8141 for Retinal Diseases, SZN-8143 for Retinal Diseases, SZN-113 for Fuchs’ Endothelial Corneal Dystrophy and Geographic Atrophy, and SZN-413 for Retinal Diseases. SZN-8141 combines Frizzled 4 (Fzd4) agonism and Vascular Endothelial Growth Factor (VEGF) antagonism which has the potential to provide benefits over treatment with single agents for Diabetic Macular Edema (DME) and neovascular Age Related Macular Degeneration (wet AMD). SZN-8143 combines Fzd4 agonism, VEGF antagonism, and interleukin-6 (IL-6) antagonism which may have benefits over single agents for treatment of DME/wet AMD/uveitic macular edema. SZN-413 is a bi-specific antibody, designed using its SWAP technology.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- August 10th, 2021
- Public Since
- November 23rd, 2020
- No. of Shareholders
- 56
- No. of Employees
- 40
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 8,463,213
- Address
- 171 Oyster Point Blvd, Suite 400, SOUTH SAN FRANCISCO, 94080
- Web
- https://www.surrozen.com
- Phone
- +1 6504752820
- Auditors
- Ernst & Young LLP
Upcoming Events for SRZN
Similar to SRZN
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
Aclarion
NASDAQ Capital Market
FAQ
What is the Surrozen share price?
As of Today at 23:31 UTC, shares in Surrozen are trading at $9.96. This share price information is delayed by 15 minutes.
How has the Surrozen share price performed this year?
Shares in Surrozen last closed at $9.96 and the price had moved by -1.39% over the past 365 days. In terms of relative price strength the Surrozen share price has underperformed the S&P500 Index by -11.08% over the past year.
What are the analyst and broker recommendations for Surrozen?
The overall consensus recommendation for Surrozen is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Surrozen dividend yield?
Surrozen does not currently pay a dividend.
Does Surrozen pay a dividend?
Surrozen does not currently pay a dividend.
When does Surrozen next pay dividends?
Surrozen does not currently pay a dividend.
How do I buy Surrozen shares?
To buy shares in Surrozen you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Surrozen?
As of the previous close price of $9.96, shares in Surrozen had a market capitalisation of $84.29m.
Where are Surrozen shares listed?
Here are the trading details for Surrozen:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SRZN
What kind of share is Surrozen?
Based on an overall assessment of its quality, value and momentum Surrozen is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Surrozen share price forecast for 2025?
The analyst consensus target price for shares in Surrozen is $32.00. That is 221.29% above the last closing price of $9.96.
Analysts covering Surrozen currently have a consensus Earnings Per Share (EPS) forecast of -$4.22 for the next financial year.
Find out moreWhat is the trend in the Surrozen share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Surrozen. Over the past six months, its share price has underperformed the S&P500 Index by -24.37%.
As of the last closing price of $9.96, shares in Surrozen were trading -3.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Surrozen PE Ratio?
The Surrozen PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.96.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Surrozen?
We do not have data on Surrozen's directors